Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 10/20 | 0.56 |
| ▸ | TACR1 | P25103 | 7/20 | 0.52 |
| ▸ | TACR3 | P29371 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536190 | 1.00 | TACR2 (0.56) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL2990201 | 1.00 | TACR2 (0.56) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4941130 | 0.99 | TACR2 (0.55) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL4935551 | 0.90 | TACR2 (0.53) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL4940930 | 0.90 | TACR2 (0.56) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4944052 | 0.89 | TACR2 (0.52) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL4944326 | 0.89 | TACR2 (0.44) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4941661 | 0.88 | TACR2 (0.44) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL4630653 | 0.85 | TACR2 (0.54) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL4941672 | 0.85 | TACR2 (0.41) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2131842-A2 | USE OF A COMPOUND ANTAGONIST TO THE NK-2-RECEPTORS OF A NEUROKININE FOR THE PREPARATION OF DRUGS USEFUL FOR PREVENTING AND TREATING SEXUAL DYSFUNCTION | Sanofi-Aventis (FR) | 2009-12-16 | — | — | EP | claimed |
| WO-2008110697-A2 | USE OF A COMPOUND ANTAGONIST TO THE NK2 RECEPTORS OF A NEUROKININE FOR THE PREPARATION OF DRUGS USEFUL FOR PREVENTING AND TREATING SEXUAL DYSFUNCTION | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | claimed |
| US-20210401821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE | KINJO GAKUIN (JP) | 2021-12-30 | — | — | US | disclosed |
| US-20210401821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE | KINJO GAKUIN (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3881843-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE | Kyushu University, National University Corporation (JP) | 2021-09-22 | — | — | EP | disclosed |
| EP-2131842-A2 | USE OF A COMPOUND ANTAGONIST TO THE NK-2-RECEPTORS OF A NEUROKININE FOR THE PREPARATION OF DRUGS USEFUL FOR PREVENTING AND TREATING SEXUAL DYSFUNCTION | Sanofi-Aventis (FR) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008110697-A2 | USE OF A COMPOUND ANTAGONIST TO THE NK2 RECEPTORS OF A NEUROKININE FOR THE PREPARATION OF DRUGS USEFUL FOR PREVENTING AND TREATING SEXUAL DYSFUNCTION | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE | IL36G, IL1B, BDKRB2 | TACR2 65/4885TACR1 42/4885TACR3 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.